Skip to main
UPB

UPB Stock Forecast & Price Target

UPB Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Upstream Bio is a clinical-stage biotechnology company developing verekitug, a TSLP receptor antagonist with potential for best-in-class efficacy in treating inflammatory diseases such as nasal polyps, asthma, and COPD. The company faces financing risks, but has enough funds to last until 2027. Their stock has seen volatility due to market sentiment, but targeting the TSLP pathway shows potential for commercial success, although uncertainties and risks remain.

Bears say

Upstream Bio is developing a novel antibody antagonist, verekitug, for the treatment of inflammatory diseases, with initial focus on severe respiratory disorders. While clinical trials have shown promising results for verekitug, the stock carries significant risks, including potential need for capital raises and volatility in the biotech market. Additionally, the Phase 3 strategy for severe asthma and chronic rhinosinusitis with nasal polyps may offer differentiation, but there is uncertainty regarding the drug's potential efficacy in COPD.

UPB has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Upstream Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Upstream Bio Inc (UPB) Forecast

Analysts have given UPB a Buy based on their latest research and market trends.

According to 6 analysts, UPB has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Upstream Bio Inc (UPB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.